Benzinga | Dec 15, 2021 07:01AM EST

Guggenheim Downgrades Adagio Therapeutics to Neutral

Guggenheim analyst Seamus Fernandez downgrades Adagio Therapeutics (NASDAQ:ADGI) from Buy to Neutral.